




RealRate

PHARMACEUTICAL 2022

Cymabay Therapeutics Inc
Rank 268 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cymabay Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cymabay Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Cymabay Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 9.4% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	191,099
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,366
Liabilities, Non-Current	695
Other Assets	10,041
Other Compr. Net Income	-21
Other Expenses	0
Other Liabilities	50,320
Other Net Income	-2,416
Other Revenues	0
Property and Equipment	1,178
Research and Development	64,542
Selling, General and Administrative Expense	23,040

Output Variable	Value in 1000 USD
Assets	202,318
Liabilities	69,381
Expenses	87,582
Revenues	0
Stockholders Equity	132,937
Net Income	-89,998
Comprehensive Net Income	-90,008
BaseVar	180,859
ECR before Limited Liability	147%
Economic Capital Ratio	266%